Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lymphokine-activated killer T-cell-originated protein kinase (PBK/TOPK) is a mitotic serine/threonine protein kinase belonging to the mitogen-activated protein kinase kinase (MAPKK) family. Under physiological conditions, its expression is highly restricted, primarily found in the testes, placenta, and activated T-lymphokine-activated killer cells. However, PBK/TOPK is aberrantly overexpressed in a wide range of human malignancies, including colorectal, breast, lung, and ovarian cancers, as well as hematological malignancies like acute myeloid leukemia (AML) and multiple myeloma. It plays a critical role in cell cycle progression, mitosis, and cytokinesis by phosphorylating downstream targets such as JNK1, p38, and histone H2AX, which promotes cell survival and proliferation while suppressing apoptosis. Consequently, PBK/TOPK has emerged as an attractive therapeutic target for oncology. Several small-molecule inhibitors, such as OTS514, OTS964, and HI-TOPK-032, have been developed to target its kinase activity. While these inhibitors have shown robust preclinical efficacy, challenges remain, including hematopoietic toxicities (such as leukocytopenia and thrombocytosis) and potential off-target activities, notably the inhibition of CDK11 by OTS964.
ATP-competitive inhibition of the kinase domain, preventing phosphorylation of downstream substrates (such as JNK1, p38, ERK, and histone H2AX) and thereby blocking cell cycle progression, inducing cytokinesis defects, and promoting apoptosis in cancer cells.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lymphokine-activated killer T-cell-originated protein kinase (PBK).